Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax.

GlobeNewsWire • Dec 12, 2025

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose.

GlobeNewsWire • Nov 18, 2025

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W.

GlobeNewsWire • Nov 12, 2025

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Emergent Biosolutions (EBS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research • Nov 7, 2025

Emergent BioSolutions: Solid Q3, Expecting Better Days To Come

Emergent BioSolutions maintains a Buy rating, supported by recent Q3 earnings beat and CEO Joe Papa's turnaround progress. EBS reported Q3 revenues of $231.1M and net income of $51.2M, surpassing guidance, with improved capital allocation and reduced net debt. Narcan sales declined year-over-year due to pricing and volume pressures, but sequential growth and strong demand signal market stabilization.

Seeking Alpha • Nov 7, 2025

Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?

Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Oct 31, 2025

Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

Emergent BioSolutions Inc. ( EBS ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Frank Vargo Joseph Papa - CEO, President & Director Richard Lindahl - Executive VP, CFO & Treasurer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Oct 30, 2025

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior year Third Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38% Raising the Full Year 2025 Revenue and Profitability Guidance Strong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN® Nasal Spray, QoQ Through Q3 2025 GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Oct 29, 2025

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $1.37 per share a year ago.

Zacks Investment Research • Oct 29, 2025

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds (65 percent) of respondents agree the likelihood of a biological attack on U.S. soil is rising, yet almost half (45 percent) believe the U.S. is unprepared for a biological attack.

GlobeNewsWire • Oct 28, 2025